0000000000650500

AUTHOR

Michelle Haber

0000-0003-2036-8817

showing 3 related works from this author

Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma

2016

Accurate assessment of neuroblastoma outcome prediction remains challenging. Therefore, this study aims at establishing novel prognostic tumor DNA methylation biomarkers. In total, 396 low- and high-risk primary tumors were analyzed, of which 87 were profiled using methyl-CpG-binding domain (MBD) sequencing for differential methylation analysis between prognostic patient groups. Subsequently, methylation-specific PCR (MSP) assays were developed for 78 top-ranking differentially methylated regions and tested on two independent cohorts of 132 and 177 samples, respectively. Further, a new statistical framework was used to identify a robust set of MSP assays of which the methylation score (i.e.…

EXPRESSIONMale0301 basic medicineGENESPROMOTERBIOMARKERSMedizinComputational biologyBiologyPHENOTYPEReal-Time Polymerase Chain ReactionCohort StudiesneuroblastomaNeuroblastoma03 medical and health sciencesPOOR-PROGNOSISSTRATIFICATIONNeuroblastomaMedicine and Health SciencesTumor Cells CulturedmedicineHumansNeoplasm StagingGeneticsDNA methylationBinding SitesComputational BiologyInfantDNADNA NeoplasmMethylationPrognosismedicine.diseaseMethyl-CpG-binding domain030104 developmental biologyDifferentially methylated regionsReal-time polymerase chain reactionRISK GROUPOncologyCpG siteSTAGE-4 NEUROBLASTOMADNA methylationbiomarkerBiomarker (medicine)CpG IslandsFemaleprognosisBiomarkersResearch PaperOncotarget
researchProduct

Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project

2012

Background: In the INRG dataset, the hypothesis that any segmental chromosomal alteration might be of prognostic impact in neuroblastoma without MYCN amplification (MNA) was tested. Methods: The presence of any segmental chromosomal alteration (chromosome 1p deletion, 11q deletion and/or chromosome 17q gain) defined a segmental genomic profile. Only tumours with a confirmed unaltered status for all three chromosome arms were considered as having no segmental chromosomal alterations. Results: Among the 8800 patients in the INRG database, a genomic type could be attributed for 505 patients without MNA: 397 cases had a segmental genomic type, whereas 108 cases had an absence of any segmental a…

OncologyCancer Researchmedicine.medical_specialtyPathologyBiologyLoss of heterozygosityneuroblastomaNeuroblastomaInternal medicineINRGmedicineHumansClinical significancegenomic profileSurvival analysisRetrospective StudiesChromosome AberrationsOncogene ProteinsN-Myc Proto-Oncogene ProteinUnivariate analysisgenetic alterationsChromosomes Human Pair 11InfantNuclear ProteinsChromosomeGenetics and GenomicsPrognosismedicine.diseaseSurvival AnalysisOncologyGenetic markerGenomic ProfileChromosomes Human Pair 17British Journal of Cancer
researchProduct

A g316a polymorphism in the ornithine decarboxylase gene promoter modulates mycn‐driven childhood neuroblastoma

2021

Simple Summary Neuroblastoma is a devasting childhood cancer in which multiple copies (amplification) of the cancer-causing gene MYCN strongly predict poor outcome. Neuroblastomas are reliant on high levels of cellular components called polyamines for their growth and malignant behavior, and the gene regulating polyamine synthesis is called ODC1. ODC1 is often coamplified with MYCN, and in fact is regulated by MYCN, and like MYCN is prognostic of poor outcome. Here we studied a naturally occurring genetic variant or polymorphism that occurs in the ODC1 gene, and used gene editing to demonstrate the functional importance of this variant in terms of ODC1 levels and growth of neuroblastoma cel…

0301 basic medicineCancer ResearchSNPSingle-nucleotide polymorphismBiologylcsh:RC254-282ArticleOrnithine decarboxylase03 medical and health sciencesneuroblastomaNeuroblastoma0302 clinical medicineNeuroblastomaGenotypeMYCNMedicine and Health SciencesTranscriptional regulationmedicineODC1neoplasmsWild typePromotermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensMolecular biology030104 developmental biologyOncology030220 oncology & carcinogenesisChildhood Neuroblastoma
researchProduct